Vasil Kisil & Partners advising Lekhim on distribution of COVID-19 vaccine

Lekhim group of companies reached an agreement with Sinovac Biotech Ltd. on distribution and production in Ukraine of vaccine against SARS-CoV-2, which causes COVID-19 illness, and acting as the exclusive supplier of the manufacturer in Ukraine entered with the Ministry of Health of Ukraine an agreement for supply of over 1.9 million doses of vaccine. CoronaVac is an inactivated vaccine. It is distributed in syringes and stored at temperature from +2 to +8 degrees Celsius. 

Vasil Kisil & Partners advised Lekhim on structuring the distribution of vaccine in Ukraine, price regulations and sales taxation, and proposed the most efficient way to formalise in contracts the relations between Lekhim and consumers, which are companies willing to facilitate their employees with vaccination, as well as other involved entities, such as Ukrainian healthcare centers and insurance companies. Vasil Kisil & Partners’ team has drafted detailed agreements according to the designed contractual structure, which take into consideration the specific terms of settlements, the instructions for storage and application of vaccine, which are necessary for safeguarding the patients' health, and ensure adequately balanced distribution of obligations and liability with respect to application of the vaccine among everyone involved in the vaccine treatment on the path from the manufacturer to the patient. 

Vasil Kisil & Partners’ team included Alexander Borodkin, Partner, and Roman Riabenko, Senior Associate.

Lekhim Group of Companies is one of the pharmaceutical leaders in Ukraine in the area of development, manufacture and sale of qualitative and affordable medicines of all therapeutic groups produced according to international GMP standards (over 200 items) and annually registers about 10 new products manufactured according to advanced technologies.

Sinovac Biotech Ltd. is a Chinese-based biopharmaceutical company that was incorporated in 1999 and focuses on the research, manufacture and commercialization of the vaccines for infectious diseases with significant unmet medical need, including vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps. Sinovac Biotech Ltd. has production capacity of 300 to 500 million doses per year.